ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2665

Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis

Zhen Yang1, Hiroshi Fujii2, Shalini Mohan1, Jorg J. Goronzy1 and Cornelia M. Weyand3, 1Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 2Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 3Medicine, Stanford University School of Medicine, Stanford, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: In RA, autoimmunity precedes clinical symptoms by a decade and persists unabated even when downstream inflammation is well controlled; exposing lymphocytes to chronic stimulation and enforcing adaptation to persistent stress. T cells undergo rapid and extensive clonal expansion with a fairly unique need to greatly enhance metabolic activities and fulfill their energy needs by up-regulating aerobic glycolysis as well as autophagy. Glycolytic flux is mainly controlled by 6-phosphofructo-1-kinase, with its allosteric activator fructose 2,6-bisphosphate as a key regulator of the glycolytic pathway. The enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3) generates fructose-2,6-bisphosphate and, hence, critically regulates the glycolytic rate under normal and pathophysiological conditions.

Methods: CD4+CD45RO– T cells purified from the blood of RA patients (n=77) and age-matched controls were stimulated by TCR crosslinking. Glucose consumption, intracellular ATP and lactate production were quantified. Expression of 33 glycolysis-associated genes was profiled by RT-PCR. Protein levels of PFKFB3 and the autophagy marker LC3II were measured by Western blotting. Glycolytic flux and autophagic signaling were blocked through the PFKFB3 inhibitor N-BrEt or the autophagy inhibitor 3-methyladenine.

Results: Compared to control CD4 T cells, RA CD4 T cells respond to stimulation-induced metabolic needs with impaired glucose consumption (p=0.015), diminished ATP production (p<0.001)and reduced lactate release (p<0.001); all indicative of a defect in glycolytic flux. RA T cells express normal densities of glucose receptors but consistently fail to up-regulate PFKFB3 (p=0.012) and induce insufficient amounts of LC3II (p=0.032). Deficiency in glucose metabolism and autophagy is associated with increased apoptosis (p=0.003). This phenotype is reproduced in control T cells by knockdown of PFKFB3 or blocking autophagic signaling. Overexpression of ectopic PFKFB3 in RA T cells restores intracellular ATP (p=0.009) and lactate production (p=0.024) and conveys apoptotic resistance. Restoring PFKFB3 in RA T cells also rectifies the autophagic defect (p=0.024). Energy deprivation is a stable phenotype of RA T cells, independent from disease activity and duration.

Conclusion: The inducible glycolytic rate-limiting enzyme PFKFB3 is repressed in RA T cells, resulting in deficient glucose utilization. The energy deprivation is aggravated by insufficient access to cell-internal energy resources and renders RA T cells apoptosis sensitive. Resetting the immune system in RA will require the repair of these metabolic abnormalities as they strain immune homeostasis and sustain chronic immune stress.


Disclosure:

Z. Yang,
None;

H. Fujii,
None;

S. Mohan,
None;

J. J. Goronzy,
None;

C. M. Weyand,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-reprogramming-of-autoimmune-t-cells-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology